Can Austedo Be Used in a Patient with a Pacemaker and Atrial Fibrillation?
Austedo (deutetrabenazine) can be used in patients with a pacemaker and atrial fibrillation, but requires careful cardiac monitoring due to QT prolongation risk, particularly given the potential for drug interactions and the underlying cardiac conduction abnormalities that may have necessitated pacemaker placement.
Key Safety Considerations from FDA Labeling
The FDA label for Austedo explicitly warns about QTc prolongation 1. While the degree of QT prolongation is described as "not clinically significant when administered within the recommended dosage range," Austedo should be avoided in patients with a history of cardiac arrhythmias 1.
Specific Risk Factors That Increase Concern
The risk of torsades de pointes and sudden death increases with:
- Bradycardia (relevant if pacemaker-dependent)
- Hypokalemia or hypomagnesemia
- Concomitant use of other QT-prolonging drugs
- Congenital long QT syndrome 1
The Atrial Fibrillation Component
Your patient's atrial fibrillation adds complexity. Multiple guidelines discuss quinidine (structurally unrelated to Austedo but relevant for QT considerations) as causing QT prolongation and torsades de pointes when used for AF cardioversion 2, 3, 4, 5. The concern is that patients with AF often have:
- Underlying structural heart disease
- Electrolyte abnormalities from diuretics
- Concurrent use of rate-control medications (beta-blockers, calcium channel blockers)
The Pacemaker Factor
A pacemaker does NOT eliminate QT prolongation risk. The pacemaker addresses bradycardia and conduction block but cannot prevent drug-induced ventricular arrhythmias like torsades de pointes. In fact, pacemaker dependency may indicate:
- Advanced conduction system disease
- Increased vulnerability to proarrhythmic effects
- Potential for pacemaker-mediated tachycardia interactions
Critical Pitfall to Avoid
Do not assume the pacemaker provides protection against Austedo's cardiac effects. The FDA label specifically states Austedo "should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias" 1. Atrial fibrillation qualifies as a cardiac arrhythmia history.
Practical Management Algorithm
If you decide to proceed:
Baseline assessment:
- Obtain baseline ECG with QTc measurement
- Check electrolytes (potassium, magnesium)
- Review all concurrent medications for QT-prolonging agents
- Verify pacemaker settings and dependency
Initiation monitoring:
- Start at lowest dose (6 mg for Austedo XR or twice-daily dosing for regular Austedo)
- Repeat ECG after dose stabilization
- Monitor for QTc >500 ms (contraindication per FDA guidance on similar agents)
Ongoing surveillance:
- Regular ECG monitoring during dose titration
- Maintain normal electrolytes
- Watch for symptoms: syncope, palpitations, dizziness
Drug interaction vigilance:
- Avoid combining with other QT-prolonging medications
- Be cautious with CYP2D6 inhibitors that increase Austedo levels
When to Absolutely Avoid
Do not use Austedo if:
- Patient has history of torsades de pointes
- Baseline QTc >500 ms
- Patient is on multiple QT-prolonging agents that cannot be discontinued
- Severe bradycardia despite pacing
- Recent cardiac decompensation
Alternative Consideration
Given the FDA's explicit caution about using Austedo in patients with cardiac arrhythmia history 1, and the fact that your patient has both AF and requires a pacemaker (suggesting significant cardiac pathology), you should strongly consider whether the benefits of treating chorea or tardive dyskinesia outweigh these cardiac risks. Alternative VMAT2 inhibitors or non-pharmacologic approaches may be safer, though this requires individualized risk-benefit assessment based on the severity of the movement disorder being treated.
The presence of a pacemaker does not make Austedo safe—it requires enhanced monitoring and careful patient selection.